Targeted Oncology

雜志介紹

Targeted Oncology雜志介紹

《Targeted Oncology》是一本以English為主的未開放獲取國際優秀期刊，中文名稱靶向腫瘤學，本刊主要出版、報道醫學-ONCOLOGY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為4.4，最新CiteScore 指數為8.4。

本刊近期中國學者發表的論文主要有：

• Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

  Author: Popat, Sanjay; Ahn, Myung-Ju; Ekman, Simon; Leighl, Natasha B.; Ramalingam, Suresh S.; Reungwetwattana, Thanyanan; Siva, Shankar; Tsuboi, Masahiro; Wu, Yi-Long; Yang, James Chih-Hsin

• Distribution of <Emphasis Type="Italic">ALK</Emphasis> Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib

  Author: Yudong Su, Xiang Long, Yang Song, Peng Chen, Shanqing Li, Huaxia Yang, Pancheng Wu, Yanyu Wang, Zhongxing Bing, Zhili Cao, Lei Cao, Yijun Wu, Zhe Zhang, Jing Liu, Bing Li, Jianxing Xiang, Ke Ma, Tengfei Zhang, Lu Zhang, Xinru Mao, Hao Liu, Puyuan Xing, Naixin Liang

• Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study

  Author: Xiaonan Hong, Yuqin Song, Huiqiang Huang, Bing Bai, Huilai Zhang, Xiaoyan Ke, Yuankai Shi, Jun Zhu, Guodong Lu, Stefan Liebscher, Chunxiao Cai

• Clinical Management of Non-Small Cell Lung Cancer with Concomitant <Emphasis Type="Italic">EGFR</Emphasis> Mutations and <Emphasis Type="Italic">ALK</Emphasis> Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib

  Author: Yiming Zhao, Shuyuan Wang, Bo Zhang, Rong Qiao, Jianlin Xu, Lele Zhang, Yanwei Zhang, Baohui Han

英文介紹

Targeted Oncology雜志英文介紹

Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes:

Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches.

Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways.

Current Opinion articles that place interesting areas in perspective.

Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations.

Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement.

Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.